Dynavax Technologies Corporation (DVAX) vs. Its Rivals Financial Survey
Dynavax Technologies Corporation (NASDAQ: DVAX) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Dynavax Technologies Corporation to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
Insider and Institutional Ownership
60.2% of Dynavax Technologies Corporation shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.9% of Dynavax Technologies Corporation shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Dynavax Technologies Corporation has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Dynavax Technologies Corporation’s competitors have a beta of 6.61, indicating that their average share price is 561% more volatile than the S&P 500.
Earnings and Valuation
This table compares Dynavax Technologies Corporation and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Dynavax Technologies Corporation||$7.71 million||-$94.16 million||-9.35|
|Dynavax Technologies Corporation Competitors||$473.33 million||$171.77 million||-7.06|
Dynavax Technologies Corporation’s competitors have higher revenue and earnings than Dynavax Technologies Corporation. Dynavax Technologies Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Dynavax Technologies Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dynavax Technologies Corporation||-1,323.99%||-92.09%||-78.45%|
|Dynavax Technologies Corporation Competitors||-5,459.03%||-446.95%||-41.61%|
This is a breakdown of current ratings and recommmendations for Dynavax Technologies Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dynavax Technologies Corporation||0||0||5||0||3.00|
|Dynavax Technologies Corporation Competitors||728||3173||11798||264||2.73|
Dynavax Technologies Corporation presently has a consensus price target of $27.80, suggesting a potential upside of 20.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.54%. Given Dynavax Technologies Corporation’s competitors higher probable upside, analysts plainly believe Dynavax Technologies Corporation has less favorable growth aspects than its competitors.
Dynavax Technologies Corporation competitors beat Dynavax Technologies Corporation on 7 of the 12 factors compared.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.